LUMO News and Press, Lumos Pharma Inc. From 11/07/23

2023-11-07 17:22:37 ET More on Lumos Pharma Lumos Pharma, Inc. (LUMO) Q2 2023 Earnings Call Transcript Lumos stock rockets nearly 100% in after-hours trading on study updates Seeking Alpha’s Quant Rating on Lumos Pharma Historical earnings data for Lum...

2023-11-07 16:47:23 ET More on Lumos Pharma Lumos Pharma, Inc. (LUMO) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Lumos Pharma Historical earnings data for Lumos Pharma Financial information for Lumos Pharma For further det...

-- Phase 2 Data for Potentially the First Oral Therapeutic for PGHD Met All Primary and Secondary Endpoints with Supportive Evidence to Advance to Phase 3 – -- OraGrowtH210 Trial Results Show LUM-201 Dose of 1.6 mg/kg Achieves AHVs of 8.2 cm/yr at 6 Months and 8.0 cm/yr at 12...

OraGrowtH210 Results Show LUM-201 Dose of 1.6 mg/kg Achieves Annualized Height Velocities (AHV) of 8.2 cm/yr at 6 Months and 8.0 cm/yr at 12 Months, Comparable to Growth Rates for Moderate PGHD Population Delta at 6 and 12-month AHV Between Optimal LUM-201 Dose of 1.6 mg/kg and rhGH Compa...

Deconvolution Analysis Shows 60% Increase in GH Secretion, Comparable to Established Values in Normal Children Analysis Shows Annualized Height Velocity Increased ~62% Compared to Baseline Data Support LUM-201 Mechanism of Action in Moderate PGHD Patient Population AUSTI...

AUSTIN, Texas, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that an abstract reviewing interim d...

AUSTIN, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the H...

AUSTIN, Texas, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that an independent, key opinion lead...

2023-08-09 22:27:09 ET Lumos Pharma, Inc. (LUMO) Q2 2023 Earnings Conference Call August 09, 2023 4:30 PM ET Company Participants Lisa Miller – Senior Director of Investor Relations Rick Hawkins – Chief Executive Officer and Chairman Lori Lawley &#x...

2023-08-09 16:37:39 ET Lumos Pharma press release ( NASDAQ: LUMO ): Q2 GAAP EPS of -$1.09 misses by $0.02 . Revenue of $0.53M (+32.5% Y/Y) beats by $0.33M . Ended the quarter on June 30, 2023 with cash, cash equivalents and short-term investments totaling ...